ACE2 and COVID-19: Since liver injury in COVID-19 is likely caused by direct viral toxicity due to high ACE2 expression on hepatocytes and cholangiocytes [19,34], it is plausible the possibly lower ALI rate in patients who received remdesivir can be partially explained by inhibition of viral replication systemically and in the liver per se.